DELRAY BEACH, Fla., Sept. 9, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has shipped three M-BAND (Microfluidic-based Bioagent Autonomous Networked Detector) systems to Aberdeen Proving Ground ("APG") in Maryland for continued testing to protect U.S. warfighters as part of The Joint United States Forces Korea Portal and Integrated Threat Recognition (JUPITR) program. APG is recognized as one of the world's most important research and development, testing and evaluation facilities for military weapons and equipment, and supports military and civilian scientists, research engineers, technicians and administrators.
PositiveID previously announced an agreement with a large government contractor to support the U.S. Department of Defense JUPITR Program, led by the Joint Program Executive Office for Chemical and Biological Defense and supported by the U.S. Army Edgewood Chemical Biological Center, to provide unique biological detection capabilities for advanced bio-surveillance on the Korean peninsula. As part of this program, M-BAND is being tested and evaluated to baseline performance, reliability, maintainability, ease of use, and cost of operation to provide the "best of breed" and most affordable options for the U.S. Army and U.S. Air Force. PositiveID has already shipped one M-BAND unit to the Korean peninsula for testing under the program.
"We are honored to provide our M-BAND systems to support and protect our warfighters and allies overseas," said William J. Caragol, Chairman and CEO of PositiveID. "We believe that this thorough evaluation of our M-BAND systems will show that our product can provide a critical defense against attacks of bioterror."
Supporting organizations for JUPITR include the Department of Homeland Security, Office of the Assistant Secretary of Defense for Health Affairs, Health Affairs and Defense Threat Reduction Agency.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that this thorough evaluation of PositiveID's M-BAND systems will show that the Company's product can provide a critical defense against attacks of bioterror, and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the bio-threat detection and rapid medical testing sectors; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 11, 2014, and 10-Qs filed on August 14, 2014, May 20, 2014, and November 19, 2013, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: PositiveID Corporation Allison Tomek 561-805-8000 firstname.lastname@example.org